Approval of antineoplastic agents in India: comparison with the US and EU regions
Keywords:Oncology, anticancer drug, marketing approval, drug lag, new drug development
Background: The antineoplastic drugs are prescribed for the treatment of cancer, which is an important cause of mortality in India; therefore, a drug lag in the availability of antineoplastic drugs is a direct threat to life. The present study was undertaken to assess the drug lag for new antineoplastic agents in India compared with that in the United States (US) or European Union (EU).
Methods: The new antineoplastic agents approved in the United States, European Union and India between 1999 and 2011 were identified and information was gathered primarily from the websites of regulatory agencies of the three regions. We assessed absolute and relative drug lag for new antineoplastic agents approved in the three regions.
Results: Of the 70 new antineoplastic agents, 64 (91.42%) were approved in the United States, 54 (77.14%) in the European Union and 44 (62.85%) in India. The US was the first to approve 59 (84.28%) out of the 70 new antineoplastic agents, the EU was the first to approve 9 (12.85%) and India was the first to approve 2 (2.85%). The median approval lag for India (26.35 months) was higher as compared to the United States (0 month) and European Union (7.3 months).
Conclusions: This study confirms that India’s drug lag in the case of new antineoplastic agents is higher as compared to the US and EU. Further detailed analyses are necessary to find the reasons and impacts of drug lag for antineoplastic agents in India.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R et al. Cancer mortality in India: a nationally representative survey. Lancet 2012; 379:1807-16.
Reichert JB, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008; 13:30-7.
Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med 2011; 17:297-303.
Clinton W, Gore A: Reinventing the regulation of cancer drugs: National performance review, 1996. Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4191B1_01_03-Reinvent-Cancer-Drugs.pdf. Accessed 9 April 2012.
Report of the working group on drugs and pharmaceuticals for the eleventh five-year plan (2007-2012), Planning commission of India. Available at http://planningcommission.nic.in/aboutus/committee/wrkgrp11/wg11_pharma.pdf. Accessed 3 April 2012.
U.S. Food and Drug Administration. NME drug and new biologic approvals. Available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121136.htm. Accessed 19 March 2012.
European Medicines Agency. The European Public Assessment Report. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&jsenabled=true. Accessed 19 March 2012.
The Central Drugs Standard Control Organization (CDSCO). List of drug approved for marketing in India. Available at http://cdsco.nic.in/listofdrugapprovedmain.html. Accessed 19 March 2012.
National Cancer Institute. Fact sheet: targeted cancer therapies, 2012. Available at http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted#q1. Accessed 9 April 2012.
European Medicines Agency. Merck Sharp & Dohme Ltd withdraws its marketing authorisation application for Vorinostat MSD. February 17, 2009. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000115.sjsp&jsenabled=true. Accessed 9 April 2012.
U.S. questions India's IP regime after Nexavar move. By Tracy Staton, March 27, 2012. Available at http://www.fiercepharma.com/story/us-questions-indias-ip-regime-after-nexavar-move/2012-03-27. Accessed 9 April 2012.
Yonemori K. Hirakawa A et al. The notorious “drug lag” for oncology drugs in Japan. Invest New Drugs 2011; 29:706-12.